Home » Stocks » ATRC

AtriCure, Inc. (ATRC)

Stock Price: $77.67 USD -0.04 (-0.05%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 3.55B
Revenue (ttm) 212.58M
Net Income (ttm) -48.66M
Shares Out 45.63M
EPS (ttm) -1.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $77.67
Previous Close $77.71
Change ($) -0.04
Change (%) -0.05%
Day's Open 77.80
Day's Range 77.01 - 80.44
Day's Volume 246,599
52-Week Range 34.04 - 80.44

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AtriCure (ATRC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...

1 week ago - Zacks Investment Research

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and Dr...

1 week ago - Business Wire

AtriCure (ATRC) delivered earnings and revenue surprises of 7.32% and 5.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 week ago - Zacks Investment Research

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 11.11% year over year to ($0.32), which beat the ...

1 week ago - Benzinga

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced first quarter 20...

1 week ago - Business Wire

AtriCure (NASDAQ:ATRC) announces its next round of earnings this Tuesday, April 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q1 earnings announcement.

1 week ago - Benzinga

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine...

1 month ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...

1 month ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

2 months ago - Business Wire

Shares of AtriCure (NASDAQ:ATRC) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 51.35% year over year to ($0.18), which beat the estimat...

2 months ago - Benzinga

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced fourth quarter 2...

2 months ago - Business Wire

On Tuesday, February 23, AtriCure (NASDAQ:ATRC) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.

2 months ago - Benzinga

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

2 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...

3 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial ...

3 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it has rece...

4 months ago - Business Wire

AtriCure (ATRC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

4 months ago - Business Wire

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

5 months ago - Zacks Investment Research

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

5 months ago - Business Wire

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

AtriCure (ATRC) delivered earnings and revenue surprises of 67.65% and 13.69%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced third quarter 20...

6 months ago - Business Wire

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

6 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will rel...

6 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company...

8 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced today that Andy Wade i...

9 months ago - Business Wire

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that th...

9 months ago - Business Wire

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

AtriCure (ATRC) delivered earnings and revenue surprises of 64.29% and 16.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Shares of AtriCure (NASDAQ:ATRC) were flat in after-market trading after the company reported Q2 results.

9 months ago - Benzinga

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2...

9 months ago - Business Wire

AtriCure, Inc. (ATRC) CEO Michael Carrel on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AtriCure (ATRC) delivered earnings and revenue surprises of 5.26% and 0.27%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AtriCure has moved higher as of late, but there could definitely be trouble on the horizon for this company.

1 year ago - Zacks Investment Research

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.

1 year ago - Zacks Investment Research

AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

President, CEO, & Director of Atricure Inc (NASDAQ:ATRC) Michael H Carrel (insider trades) sold 25,000 shares of ATRC on 07/10/2019 at an average price of $32 a share.

1 year ago - GuruFocus

AtriCure's (ATRC) CEO Mike Carrel on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 years ago - Zacks Investment Research

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Aug 5, 2005
Stock Exchange
NASDAQ
Ticker Symbol
ATRC
Full Company Profile

Financial Performance

In 2020, AtriCure's revenue was $206.53 million, a decrease of -10.52% compared to the previous year's $230.81 million. Losses were -$48.16 million, 36.8% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for AtriCure stock is "Strong Buy." The 12-month stock price forecast is 82.71, which is an increase of 6.49% from the latest price.

Price Target
$82.71
(6.49% upside)
Analyst Consensus: Strong Buy